Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

17.80 +0.51 (+2.95%)
Streaming Delayed Price Updated: 10:57 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 Next >
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
From Pulse Biosciences
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.